4.7 Article

Robustness of convolutional neural networks in recognition of pigmented skin lesions

Journal

EUROPEAN JOURNAL OF CANCER
Volume 145, Issue -, Pages 81-91

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2020.11.020

Keywords

Artificial intelligence; Machine learning; Deep learning; Neural networks; Dermatology; Skin neoplasms; Melanoma; Nevus

Categories

Funding

  1. Federal Ministry of Health, Berlin, Germany

Ask authors/readers for more resources

A high robustness is a basic requirement for AI-based image analysis systems in clinical practice. This study quantified the impact of minor image perturbations on CNN-mediated skin lesion classification and evaluated three possible solutions. Results showed that minor image changes may affect CNNs' robustness, but existing methods can reduce brittleness to some extent.
Background: A basic requirement for artificial intelligence (AI)-based image analysis systems, which are to be integrated into clinical practice, is a high robustness. Minor changes in how those images are acquired, for example, during routine skin cancer screening, should not change the diagnosis of such assistance systems. Objective: To quantify to what extent minor image perturbations affect the convolutional neural network (CNN)-mediated skin lesion classification and to evaluate three possible solutions for this problem (additional data augmentation, test-time augmentation, anti-aliasing). Methods: We trained three commonly used CNN architectures to differentiate between dermoscopic melanoma and nevus images. Subsequently, their performance and susceptibility to minor changes ('brittleness') was tested on two distinct test sets with multiple images per lesion. For the first set, image changes, such as rotations or zooms, were generated artificially. The second set contained natural changes that stemmed from multiple photographs taken of the same lesions. Results: All architectures exhibited brittleness on the artificial and natural test set. The three reviewed methods were able to decrease brittleness to varying degrees while still maintaining performance. The observed improvement was greater for the artificial than for the natural test set, where enhancements were minor. Conclusions: Minor image changes, relatively inconspicuous for humans, can have an effect on the robustness of CNNs differentiating skin lesions. By the methods tested here, this effect can be reduced, but not fully eliminated. Thus, further research to sustain the performance of AI classifiers is needed to facilitate the translation of such systems into the clinic. (C) 2020 The Author(s). Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Dermatology

Treatment of the Candida subspecies Candida albicans and Candida parapsilosis with two far-UVC sources to minimise mycoses in clinical practice

Johannes Schleusener, Silke B. Lohan, Loris Busch, Kamran Ghoreschi, Neysha Lobo Ploch, Stefanie May, Simone Vogel, Jurgen Eberle, Martina C. Meinke

Summary: Fungal infections have been increasing and becoming resistant to common drugs. UVC light at wavelength 254 nm has shown eradication effects on microorganisms but is highly carcinogenic and mutagenic. To avoid harming skin cells, researchers tested the antifungal effects of UVC light at wavelengths 222 nm and 233 nm. They found that microbicidal doses could be achieved at 40 mJ/cm(2) for both wavelengths, resulting in minimal skin damage.

MYCOSES (2023)

Article Oncology

Multimodal integration of image, epigenetic and clinical data to predict BRAF mutation status in melanoma

Lucas Schneider, Christoph Wies, Eva I. Krieghoff-Henning, Tabea-Clara Bucher, Jochen S. Utikal, Dirk Schadendorf, Titus J. Brinker

Summary: In this study, the contribution of different data types in a combined classifier for predicting BRAF mutation status in melanoma was analyzed. The multimodal classifier showed improved generalisability compared to individual classifiers.

EUROPEAN JOURNAL OF CANCER (2023)

Article Oncology

Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma

Alexander C. J. van Akkooi, Dirk Schadendorf, Alexander M. M. Eggermont

Summary: Sentinel lymph node biopsy (SLNB) was introduced in the 1990s to identify patients who may benefit from completion lymph node dissection. SLNB staging has been found to be the best for staging melanoma. Adjuvant systemic therapy and biomarkers are emerging, which might reduce the need for SLNB staging in the future.

EUROPEAN JOURNAL OF CANCER (2023)

Article Dermatology

Real-world outcomes using PD-1 antibodies and BRAF plus MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

Katharina Schumann, Cornelia Mauch, Kai-Christian Klespe, Carmen Loquai, Ulrike Nikfarjam, Max Schlaak, Larissa Akcetin, Peter Koelblinger, Magdalena Hoellwerth, Markus Meissner, Guelcin Mengi, Andreas Dominik Braun, Miriam Mengoni, Reinhard Dummer, Joanna Mangana, Mihaela-Anca Sindrilaru, Dan Radmann, Christine Hafner, Johann Freund, Klemens Rappersberger, Felix Weihsengruber, Frank Meiss, Lydia Reinhardt, Friedegund Meier, Barbara Rainer, Erika Richtig, Julia Maria Ressler, Christoph Hoeller, Thomas Eigentler, Teresa Amaral, Wiebke K. Peitsch, Uwe Hillen, Wolfgang Harth, Fabian Ziller, Kerstin Schatton, Thilo Gambichler, Laura Susok, Lara Valeska Maul, Heinz Laubli, Dirk Debus, Carsten Weishaupt, Sevil Boerger, Katharina Sievers, Sebastian Haferkamp, Veronika Zenderowski, Van Anh Nguyen, Marina Wanner, Ralf Gutzmer, Patrick Terheyden, Katharina Kaehler, Steffen Emmert, Alexander Thiem, Michael Sachse, Silke Gercken-Riedel, Kjell Matthias Kaune, Kai-Martin Thoms, Lucie Heinzerling, Markus Vincent Heppt, Sabine Tratzmiller, Wolfram Hoetzenecker, Angela Oellinger, Andreas Steiner, Tobias Peinhaupt, Maurizio Podda, Sabine Schmid, Uwe Wollina, Tilo Biedermann, Christian Posch

Summary: This real-world study examines the clinical outcomes of adjuvant melanoma treatment using PD-1 antibodies and BRAF + MEK inhibitors in specialized skin cancer centers in Germany, Austria, and Switzerland. The results show that patients treated with PD-1 antibodies have a lower 12-month recurrence rate compared to patients treated with BRAF + MEK inhibitors. Additionally, PD-1 antibody treatment is not affected by BRAF mutation status.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study

Alexander Thiem, Pegah Mashhadiakbar, Christiane Cussigh, Jessica C. Hassel, Imke Grimmelmann, Ralf Gutzmer, Max Schlaak, Markus Heppt, Pia Duecker, Svea Huening, Lena Schulmeyer, Bastian Schilling, Sebastian Haferkamp, Mirjana Ziemer, Rose K. C. Moritz, Victoria Hagelstein, Patrick Terheyden, Christian Posch, Maria R. Gaiser, Peter Kropp, Steffen Emmert, Britta Mueller, Julia K. Tietze

Summary: This study investigated the impact of disease and treatment on the daily life of patients receiving systemic therapy for melanoma. The results showed that immune checkpoint inhibition might be preferred over targeted therapy in terms of quality of life and adverse events in the adjuvant setting, and older patients with melanoma were less impacted by their disease and more satisfied with their treatment.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus-19 vaccine-associated lymphadenopathy

Jan-Malte Placke, Delphine Mertens, Alpaslan Tasdogan, Eleftheria Chorti, Dirk Schadendorf, Selma Ugurel, Alexander Roesch, Ingo Stoffels, Joachim Klode

Summary: This study demonstrates that multispectral optoacoustic tomography (MSOT) can differentiate between benign and malignant lymphadenopathy by measuring the levels of oxyhemoglobin and deoxyhemoglobin in lymph nodes. It offers a noninvasive approach to avoid unnecessary lymph node biopsies and surgeries.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Editorial Material Otorhinolaryngology

Multimodality Therapy for Locally Advanced Cutaneous Squamous Cell Carcinoma

Marlene Garzarolli, Olimpiu Bota, Matthias Meinhardt, Tareq Juratli, Friedegund Meier

Summary: This case report illustrates the successful treatment of an elderly patient with advanced squamous cell carcinoma using the monoclonal antibody cemiplimab, leading to complete remission. The interdisciplinary approach and surgical intervention also contributed to the patient's positive outcome.

LARYNGO-RHINO-OTOLOGIE (2023)

Article Oncology

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

Cindy Franklin, Peter Mohr, Leonie Bluhm, Friedegund Meier, Marlene Garzarolli, Michael Weichenthal, Katharina Kaehler, Imke Grimmelmann, Ralf Gutzmer, Jochen Utikal, Patrick Terheyden, Rudolf Herbst, Sebastian Haferkamp, Claudia Pfoehler, Andrea Forschner, Ulrike Leiter, Fabian Ziller, Frank Meiss, Jens Ulrich, Alexander Kreuter, Christoffer Gebhardt, Julia Welzel, Bastian Schilling, Martin Kaatz, Karin Scharfetter-Kochanek, Edgar Dippel, Dorothee Nashan, Michael Sachse, Carsten Weishaupt, Harald Loeffler, Thilo Gambichler, Carmen Loquai, Lucie Heinzerling, Stephan Grabbe, Dirk Debus, Gaston Schley, Jessica C. Hassel, Gerhard Weyandt, Maike Trommer, Georg Lodde, Jan-Malte Placke, Lisa Zimmer, Elisabeth Livingstone, Juergen Christian Becker, Susanne Horn, Dirk Schadendorf, Selma Ugurel

Summary: This study investigated the impact of first-line therapy on the incidence of brain metastasis and survival outcomes in patients with advanced melanoma. It found that BRAF mutant patients treated with PD-1 +/- CTLA-4 inhibitors had a lower occurrence and delayed development of brain metastasis compared to BRAF+MEK targeted therapy. Furthermore, first-line therapy with CTLA-4+PD-1 showed superior overall survival compared to PD-1 and BRAF+MEK.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Physics, Particles & Fields

Search for Bs0 → l∓τ± with the semi-leptonic tagging method at Belle

L. Nayak, S. Nishida, A. Giri, I. Adachi, H. Aihara, D. M. Asner, H. Atmacan, V. Aulchenko, T. Aushev, R. Ayad, V. Babu, S. Bahinipati, S. Banerjee, M. Bauer, P. Behera, K. Belous, J. Bennett, M. Bessner, B. Bhuyan, D. Biswas, D. Bodrov, J. Borah, A. Bozek, M. Bracko, P. Branchini, T. E. Browder, A. Budano, M. Campajola, D. Cervenkov, M. -c. Chang, B. G. Cheon, K. Chilikin, H. E. Cho, K. Cho, S. -k. Choi, Y. Choi, S. Choudhury, D. Cinabro, J. Cochran, S. Das, N. Dash, G. De Nardo, G. De Pietro, R. Dhamija, F. Di Capua, J. Dingfelder, Z. Dolezal, T. V. Dong, D. Dossett, S. Dubey, D. Epifanov, T. Ferber, D. Ferlewicz, B. G. Fulsom, R. Garg, V. Gaur, P. Goldenzweig, E. Graziani, T. Gu, Y. Guan, S. Halder, T. Hara, K. Hayasaka, H. Hayashii, M. T. Hedges, D. Herrmann, W. -s. Hou, C. -l. Hsu, T. Iijima, K. Inami, G. Inguglia, N. Ipsita, A. Ishikawa, R. Itoh, M. Iwasaki, W. W. Jacobs, E. -j. Jang, S. Jia, Y. Jin, K. K. Joo, A. B. Kaliyar, T. Kawasaki, C. Kiesling, C. H. Kim, D. Y. Kim, K. -h. Kim, Y. -k. Kim, K. Kinoshita, P. Kodys, T. Konno, A. Korobov, S. Korpar, E. Kovalenko, P. Krizan, P. Krokovny, T. Kuhr, M. Kumar, R. Kumar, K. Kumara, A. Kuzmin, Y. -j. Kwon, S. C. Lee, J. Li, L. K. Li, Y. Li, J. Libby, K. Lieret, Y. -r. Lin, D. Liventsev, T. Luo, Y. Ma, M. Masuda, T. Matsuda, S. K. Maurya, F. Meier, M. Merola, F. Metzner, K. Miyabayashi, R. Mizuk, G. B. Mohanty, I. Nakamura, M. Nakao, Z. Natkaniec, A. Natochii, N. K. Nisar, S. Ogawa, H. Ono, P. Oskin, P. Pakhlov, G. Pakhlova, T. Pang, S. Pardi, J. Park, S. -h. Park, A. Passeri, S. Paul, T. K. Pedlar, R. Pestotnik, L. E. Piilonen, T. Podobnik, E. Prencipe, M. T. Prim, A. Rostomyan, N. Rout, G. Russo, S. Sandilya, A. Sangal, L. Santelj, V. Savinov, G. Schnell, C. Schwanda, A. J. Schwartz, Y. Seino, K. Senyo, M. E. Sevior, M. Shapkin, C. Sharma, J. -g. Shiu, A. Sibidanov, E. Solovieva, M. Staric, M. Sumihama, T. Sumiyoshi, M. Takizawa, K. Tanida, F. Tenchini, K. Trabelsi, M. Uchida, Y. Unno, K. Uno, S. Uno, P. Urquijo, S. E. Vahsen, G. Varner, K. E. Varvell, A. Vinokurova, D. Wang, M. -z. Wang, S. Watanuki, E. Won, B. D. Yabsley, W. Yan, J. Yelton, Y. Yook, C. Z. Yuan, L. Yuan, Y. Yusa, Y. Zhai, Z. P. Zhang, V. Zhilich, V. Zhukova

Summary: In this study, we searched for lepton-flavor-violating decays B-s(0) -> l(-/+) tau(+/-) using the full data sample collected at the Belle detector. No evidence for B-0(s) -> l(-/+) tau(+/-) decays was found, and upper limits on their branching fractions were set.

JOURNAL OF HIGH ENERGY PHYSICS (2023)

Article Oncology

Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial

Elias A. T. Koch, Anne Petzold, Anja Wessely, Edgar Dippel, Markus Eckstein, Anja Gesierich, Ralf Gutzmer, Jessica C. Hassel, Harald Knorr, Nicole Kreuzberg, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Markus Meissner, Peter Mohr, Claudia Pfoehler, Farnaz Rahimi, Dirk Schadendorf, Max Schlaak, Kai-Martin Thoms, Selma Ugurel, Jochen Utikal, Michael Weichenthal, Beatrice Schuler-Thurner, Carola Berking, Markus V. Heppt

Summary: Metastases of uveal melanoma predominantly spread to the liver. Liver-directed therapies (LDT) are commonly used for tumor control in patients with low response rates to systemic therapies. This study compared the outcomes of patients with metastatic UM treated with immune checkpoint blockade (ICB), with and without LDT, and found that the combination of LDT with ICB was associated with longer overall survival, improved progression-free survival, and higher treatment response rates.

FRONTIERS OF MEDICINE (2023)

Article Oncology

Extracting structured information from unstructured histopathology reports using generative pre-trained transformer 4 (GPT-4)

Daniel Truhn, Chiara M. L. Loeffler, Gustav Mueller-Franzes, Sven Nebelung, Katherine J. Hewitt, Sebastian Brandner, Keno K. Bressem, Sebastian Foersch, Jakob Nikolas Kather

Summary: The study demonstrates that large language models, like GPT-4, can extract structured data from unstructured pathology reports with high concordance to human-generated structured data, potentially enabling routine extraction of ground truth data for machine learning.

JOURNAL OF PATHOLOGY (2023)

Article Oncology

Deep learning based histological classification of adnex tumors

Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank

Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.

EUROPEAN JOURNAL OF CANCER (2024)

Proceedings Paper Computer Science, Artificial Intelligence

VECTOR-QUANTIZED LATENT FLOWS FOR MEDICAL IMAGE SYNTHESIS AND OUT-OF-DISTRIBUTION DETECTION

Firas Khader, Gustav Mueller-Franzes, Soroosh Tayebi Arasteh, Tianyu Han, Jakob Nikolas Kather, Johannes Stegmaier, Sven Nebelung, Daniel Truhn

Summary: We present an innovative method that combines out-of-distribution detection and image generation using vector-quantized autoencoder and normalizing flow models. The technique is demonstrated on a medical knee radiograph dataset, aiming to alleviate the quality control burden of radiologists and improve image standardization during acquisition.

2023 IEEE 20TH INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING, ISBI (2023)

Article Medicine, Research & Experimental

The future landscape of large language models in medicine

Jan Clusmann, Fiona R. Kolbinger, Hannah Sophie Muti, Zunamys I. Carrero, Jan-Niklas Eckardt, Narmin Ghaffari Laleh, Chiara Maria Lavinia Loeffler, Sophie-Caroline Schwarzkopf, Michaela Unger, Gregory P. Veldhuizen, Sophia J. Wagner, Jakob Nikolas Kather

Summary: This article provides a systematic and comprehensive overview of the potentials and limitations of large language models (LLMs) in clinical practice, medical research, and medical education. It highlights the potential of LLMs to democratize medical knowledge and facilitate access to healthcare, while also pointing out the risks of misinformation and scientific misconduct due to a lack of accountability and transparency.

COMMUNICATIONS MEDICINE (2023)

Meeting Abstract Gastroenterology & Hepatology

Deep learning predicts sensitivity to atezolizumab-bevacizumab from digital slides of hepatocellular carcinoma

Qinghe Zeng, Christophe Klein, Stefano Caruso, Pascale Maille, Daniela Allende, Beatriz Minguez, Massimo Iavarone, Massih Ningarhari, Andrea Casadei Gardini, Federica Pedica, Margherita Rimini, Riccardo Perbellini, Camille Boulagnon-Rombi, Alexandra Heurgue-Berlot, Marco Maggioni, Mohd. Rela, Mukul Vij, Sylvain Baulande, Patricia Legoix, Sonia Lameiras, Ismail Labgaa, Christine Sempoux, Antonia Digkilia, Narmin Ghaffari-Laleh, Jakob Nikolas Kather, Omar El Nahhas, Pooja Navale, Callie Torres, Tung-Hung Su, Rondell Graham, Maria Salcedo, Maria Bermudez, Nguyen H. Tran, Jean-Michel Pawlotsky, Gontran Verset, Eric Trepo, Maria Varela, Andres Castano-Garcia, Dominique Wendum, Giuliana Amaddeo, Helene Regnault, Marie Lequoy, Alba Diaz, Maria Reig, Pompilia Radu, Jean-Francois Dufour, Stephen Chan, Purva Gopal, Lea Bruges, Viviane Gnemmi, Jean Charles Nault, Hyungjin Rhee, Young Nyun Park, Mercedes Inarrairaegui, Josep Maria Argemi, Bruno Sangro, Antonio D'Alessio, Bernhard Scheiner, David J. Pinato, Matthias Pinter, Valerie Paradis, Aurelie Beaufrere, Simon Peter, Lorenza Rimassa, Luca Di Tommaso, Arndt Vogel, Sophie Michalak, Jerome Boursier, Nicolas Lomenie, Marianne Ziol, Julien Calderaro

JOURNAL OF HEPATOLOGY (2023)

Article Oncology

Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma

Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo

Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial

Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi

Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort

Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri

Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Impact of colorectal cancer screening on survival after metachronous metastasis

Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman

Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Sentinel-node biopsy in apparent early stage ovarian cancer: final results of a prospective multicentre study (SELLY)

Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia

Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies

Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study

Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond

Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.

EUROPEAN JOURNAL OF CANCER (2024)

Letter Oncology

Osimertinib-induced urticarial vasculitis in a patient with lung cancer: A rare cutaneous toxicity

Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Deep learning based histological classification of adnex tumors

Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank

Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction

Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen

Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases

Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li

Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.

EUROPEAN JOURNAL OF CANCER (2024)

Article Oncology

Peptide absent sequences emerging in human cancers

Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares

Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.

EUROPEAN JOURNAL OF CANCER (2024)